Sensei Biotherapeutics Files 8-K
Ticker: SNSE · Form: 8-K · Filed: Oct 17, 2025 · CIK: 1829802
| Field | Detail |
|---|---|
| Company | Sensei Biotherapeutics, Inc. (SNSE) |
| Form Type | 8-K |
| Filed Date | Oct 17, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-filing, financials
TL;DR
Sensei Biotherapeutics filed a standard 8-K on 10/17/25. Check exhibits for details.
AI Summary
Sensei Biotherapeutics, Inc. filed an 8-K on October 17, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or material events beyond the standard reporting requirements.
Why It Matters
This filing indicates Sensei Biotherapeutics is meeting its regulatory reporting obligations. Investors should review the exhibits for any specific disclosures.
Risk Assessment
Risk Level: low — The filing is a routine 8-K with no immediately apparent negative or positive material events disclosed.
Key Players & Entities
- Sensei Biotherapeutics, Inc. (company) — Registrant
- October 17, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- Rockville, MD (location) — Principal Executive Offices
FAQ
What specific event triggered this 8-K filing?
The filing indicates it is for a Regulation FD Disclosure and Financial Statements and Exhibits, but does not specify a particular triggering event beyond routine reporting.
Are there any new financial statements or exhibits attached to this filing?
Yes, the filing states 'Financial Statements and Exhibits' are included, but the specific content is not detailed in the provided text.
What is the principal business of Sensei Biotherapeutics, Inc.?
Sensei Biotherapeutics, Inc. is in the 'PHARMACEUTICAL PREPARATIONS' industry, SIC code 2834.
When is Sensei Biotherapeutics, Inc.'s fiscal year end?
The company's fiscal year ends on December 31st.
What is the Commission File Number for Sensei Biotherapeutics, Inc.?
The Commission File Number is 001-39980.
Filing Stats: 582 words · 2 min read · ~2 pages · Grade level 11.7 · Accepted 2025-10-17 08:05:36
Filing Documents
- d223319d8k.htm (8-K) — 27KB
- d223319dex991.htm (EX-99.1) — 23KB
- d223319dex992.htm (EX-99.2) — 52KB
- g223319ex99_2s10g1.jpg (GRAPHIC) — 86KB
- g223319ex99_2s11g1.jpg (GRAPHIC) — 104KB
- g223319ex99_2s12g1.jpg (GRAPHIC) — 57KB
- g223319ex99_2s13g1.jpg (GRAPHIC) — 93KB
- g223319ex99_2s14g1.jpg (GRAPHIC) — 87KB
- g223319ex99_2s15g1.jpg (GRAPHIC) — 67KB
- g223319ex99_2s16g1.jpg (GRAPHIC) — 88KB
- g223319ex99_2s17g1.jpg (GRAPHIC) — 81KB
- g223319ex99_2s18g1.jpg (GRAPHIC) — 87KB
- g223319ex99_2s19g1.jpg (GRAPHIC) — 101KB
- g223319ex99_2s1g1.jpg (GRAPHIC) — 95KB
- g223319ex99_2s20g1.jpg (GRAPHIC) — 98KB
- g223319ex99_2s21g1.jpg (GRAPHIC) — 113KB
- g223319ex99_2s22g1.jpg (GRAPHIC) — 96KB
- g223319ex99_2s23g1.jpg (GRAPHIC) — 120KB
- g223319ex99_2s24g1.jpg (GRAPHIC) — 94KB
- g223319ex99_2s25g1.jpg (GRAPHIC) — 67KB
- g223319ex99_2s26g1.jpg (GRAPHIC) — 19KB
- g223319ex99_2s27g1.jpg (GRAPHIC) — 65KB
- g223319ex99_2s28g1.jpg (GRAPHIC) — 84KB
- g223319ex99_2s29g1.jpg (GRAPHIC) — 98KB
- g223319ex99_2s2g1.jpg (GRAPHIC) — 194KB
- g223319ex99_2s30g1.jpg (GRAPHIC) — 107KB
- g223319ex99_2s31g1.jpg (GRAPHIC) — 84KB
- g223319ex99_2s32g1.jpg (GRAPHIC) — 90KB
- g223319ex99_2s33g1.jpg (GRAPHIC) — 87KB
- g223319ex99_2s34g1.jpg (GRAPHIC) — 112KB
- g223319ex99_2s35g1.jpg (GRAPHIC) — 77KB
- g223319ex99_2s36g1.jpg (GRAPHIC) — 94KB
- g223319ex99_2s37g1.jpg (GRAPHIC) — 76KB
- g223319ex99_2s38g1.jpg (GRAPHIC) — 90KB
- g223319ex99_2s39g1.jpg (GRAPHIC) — 90KB
- g223319ex99_2s3g1.jpg (GRAPHIC) — 109KB
- g223319ex99_2s40g1.jpg (GRAPHIC) — 102KB
- g223319ex99_2s41g1.jpg (GRAPHIC) — 122KB
- g223319ex99_2s42g1.jpg (GRAPHIC) — 120KB
- g223319ex99_2s43g1.jpg (GRAPHIC) — 97KB
- g223319ex99_2s44g1.jpg (GRAPHIC) — 81KB
- g223319ex99_2s45g1.jpg (GRAPHIC) — 28KB
- g223319ex99_2s4g1.jpg (GRAPHIC) — 83KB
- g223319ex99_2s5g1.jpg (GRAPHIC) — 101KB
- g223319ex99_2s6g1.jpg (GRAPHIC) — 101KB
- g223319ex99_2s7g1.jpg (GRAPHIC) — 86KB
- g223319ex99_2s8g1.jpg (GRAPHIC) — 96KB
- g223319ex99_2s9g1.jpg (GRAPHIC) — 100KB
- 0001193125-25-242007.txt ( ) — 5931KB
- snse-20251017.xsd (EX-101.SCH) — 3KB
- snse-20251017_lab.xml (EX-101.LAB) — 18KB
- snse-20251017_pre.xml (EX-101.PRE) — 11KB
- d223319d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 99.1 Press release dated October 17, 2025 99.2 Sensei Biotherapeutics, Inc. corporate presentation dated October 2025 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Sensei Biotherapeutics, Inc. Date: October 17, 2025 /s/ Christopher W. Gerry Christopher W. Gerry General Counsel and Secretary 3